Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026

SAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart on Wednesday, May 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m.